STA Pharmaceutical Co., a WuXi AppTec group company, and Regulus Therapeutics have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.   Under the agreement, STA will become a new strategic development and manufacturing partner for Regulus’ preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training...